It has been almost a year since we had any newsWith substance.This is uncharacterist of grimma.The good news is that they got the programs in the hands of physicians and patients before the pandemic hit.This should provide an uptick in usage in The pace and tempo programs as well as the biotricity agreement.I realize this is speculation and only time will tell but I knew this when I bought shares in this high risk/reward stock.// Patient Self-Monitoring Extends Physicians' Reach for Proactive Monitoring of Atrial Fibrillation Recurrence and any Arrhythmia. TORONTO, ONTARIO / ACCESSWIRE / January 6, 2020 / CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm" or the "Company"), a global provider of consumer heart monitoring and electrocardiogram ("ECG") device and software solutions, confirms market traction with orders being placed by physician groups for the newly launched HeartCheck CardiBeat Handheld ECG monitor and GEMS Mobile Smartphone app for prescribed in-home arrhythmia monitoring. Partners in Advanced Cardiac Evaluation ("PACE"), the largest arrhythmia practice in Ontario (Canada) placed a first order of the HeartCheck CardiBeat Handheld ECG monitors and is recommending its patients to use the devices for one year of in-home, self-monitoring with an emphasis on detecting a recurrence of Atrial Fibrillation ("AF") following cardiac ablation treatment for AF. The Company confirms that additional hospital affiliated physician groups have also purchased the HeartCheck CardiBeat ECG devices for evaluation in their respective practices with additional orders expected in early 2020. AF is a life-threatening arrhythmia that is difficult to treat. Cardiac ablation is a procedure commonly used to correct AF; however, AF recurrence after ablation is common and can be "silent", occuring without any symptoms, discomfort or warning to the patient (See Note 1). PACE patients will use the GEMS Mobile Smartphone app to record ECGs taken by the HeartCheck CardiBeat which will then be automatically forwarded by CardioComm's SMART Monitoring ECG service directly into the patient's cardiologist's Electronic Medical Record ("EMR"). Should any submitted ECG recordings show a recurrence of AF or a presence of other cardiac arrhythmias, the patients are contacted by PACE and follow-up visits scheduled. ECG reports generated through GEMS Mobile are eligible for medical service reimbursement in both Canada and the US. Dr. Yaariv Khaykin, Physician Lead at PACE and Chief Medical Information Officer at Southlake Regional Health Centre, stated, "We are very excited at the opportunity to introduce the use of this home-based ECG/arrhythmia monitoring technology to our patients empowering them to take greater charge of their health." The GEMS Mobile app is available in Android and Apple Smartphone compatible versions as a free downloadable app and allows users to generate unlimited ECG reports to show to their physician. The app also allows users to request their ECG to be reviewed by CardioComm's SMART Monitoring ECG reading service where the user does not have direct connectivity to their treating physician. To learn more about CardioComm's products and for further updates regarding HeartCheck ECG device integrations, please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com. Note 1: Heart Rhythm Journal - 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary About CardioComm Solutions CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485:2016 MDSAP certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada). FOR FURTHER INFORMATION PLEASE CONTACT: Etienne Grima, Chief Executive Officer 1-877-977-9425 x227 egrima@cardiocommsolutions.com investor.relations@cardiocommsolutions.com Forward-looking statements This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information. In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations). Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE: CardioComm Solutions, Inc View source version on accesswire.com: https://www.accesswire.com/572152/Physician-Groups-Order-The-HeartcheckTM-Cardibeat-For-In-Home-Arrhythmia-And-Atrial-Fibrillation-Monitoring